Eli Lilly (NYSE: LLY) delivered a stunning second quarter on August 5, blowing past Wall Street expectations on nearly every metric and raising its full-year revenue outlook. The pharmaceutical giant reported Q2 revenue of $22.97 billion — a 48% jump year-over-year that crushed the $20.69 billion consensus by more than $2.3 billion. Adjusted earnings per share came in at $8.38, towering above the $6.16 estimate — a 36% beat. The stock jumped roughly 6% on the news, pushing Lilly firmly back above the $1 trillion market cap threshold.
The engine driving everything is Lilly’s GLP-1 franchise — the diabetes and weight-loss drug duo of Mounjaro and Zepbound. Mounjaro revenue alone hit $9.9 billion for the quarter, up 91% year-over-year, with $4.8 billion in U.S. sales and a remarkable $5.2 billion from international markets — showing the global rollout is accelerating at pace. Together, Mounjaro and Zepbound accounted for roughly 98% of Lilly’s year-over-year revenue increase. CEO David Ricks framed it simply: “Lilly’s momentum continues, as we delivered 48% revenue growth and raised our full-year guidance.” For 2026, Lilly now expects revenue of $85 billion to $87 billion, up from the prior $82 billion–$85 billion range and above the $85.4 billion analyst consensus. Looking further ahead, the company is planning a BLA regulatory filing for retatrutide — its next-generation weight-loss drug — in Q1 2027, potentially opening another multi-billion-dollar growth leg.
For retail investors, Lilly represents one of the clearest structural growth stories in the market. Obesity and diabetes are chronic, global conditions with enormous unmet demand, and Lilly is capturing that market at a staggering pace. International Mounjaro sales now exceed U.S. sales, providing meaningful geographic diversification. The retatrutide pipeline adds significant optionality: if approved, it could extend Lilly’s GLP-1 dominance well into the next decade. With the stock jumping sharply on the beat, new buyers are paying a premium — but for a business growing revenue nearly 50% annually with expanding margins and a clear pipeline catalyst, that premium may be justifiable for long-term investors willing to hold through normal market volatility.
